Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596489 · ClinicalTrials.gov registry record
Objective Assessment of Sensory Nerve Fiber Sensitivity
A clinical trial, sponsored by Julia Finkel.
- Completed
- Registry status
- 16
- Enrollment target
NCT03596489: Completed study, sponsored by Julia Finkel.
NCT03596489 is a clinical trial that has completed, run by Julia Finkel. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03596489 has completed, sponsored by Julia Finkel.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
This pilot study utilizes a unique technology to determine nerve fiber sensitivity. This will allow us to determine whether this method and device can discern changes in pain intensity and type, which is predicated on differing nerve fiber sensitivities.
Primary Outcome
The primary measurable endpoint is the change in the Area Under the Curve (AUC) of the three sensory nerve fiber types that occurs as a response to tourniquet ischemia and reperfusion. The change is calculated by the difference between measurements at various time points: baseline, tourniquet application, and tourniquet release.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2023-07-11 |
What the finished NCT03596489 record still lists
NCT03596489 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03596489 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03596489 about?
NCT03596489 is a clinical study titled "Objective Assessment of Sensory Nerve Fiber Sensitivity". This pilot study utilizes a unique technology to determine nerve fiber sensitivity. This will allow us to determine whether this method and device can discern changes in pain intensity and type, which is predicated on differing nerve fiber sensitivities.
What is the current status of trial NCT03596489?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2018-06-27. Estimated completion is 2023-07-11.
Who is sponsoring clinical trial NCT03596489?
This trial is sponsored by Julia Finkel, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI